NCT00103701

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: —
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).

Conditions

• Leukemia, Myeloid, Chronic-phase
• Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Interventions

Type	Name	Description
DRUG	Dasatinib	Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.

Timeline

• Start date: 2003-11-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-02-15
• Last updated: 2011-04-14

Locations

2 sites across 1 country: United States